07:00 , Mar 21, 2016 |  BC Week In Review  |  Clinical News

AKN-028: Development discontinued

Akinion discontinued development of AKN-028 due to “a small number of patients experiencing severe liver toxicity.” The compound was in a Phase I/II trial to treat AML. Akinion said it is assessing its options, including...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Rosetta's Nordic preferences

Karolinska Development AB expects that selling a stake in some of its portfolio to a syndicate led by Rosetta Capital Ltd. will provide enough cash to advance the entire portfolio to a point at which...
01:33 , Dec 22, 2012 |  BC Extra  |  Financial News

Rosetta syndicate acquiring stake in Karolinska companies

A syndicate led by VC firm Rosetta Capital Ltd. will pay SEK220 million ($33 million) to acquire a minority stake in KDev Investments AB, a new private holding company created to house 13 portfolio companies...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Karolinska Development cancer news

Karolinska formed subsidiary KDev Oncology AB to focus on cancer. The subsidiary will hold projects from portfolio companies Akinion Pharmaceuticals AB (Solna, Sweden) and GliGene AB (Stockholm, Sweden). Karolinska said Carl Harald Janson,...